OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT reports.

Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump. Newsweek has contacted OpenAI and the White House for comment via email.

Sam Altman's OpenAI is backing a new AI initiative from a group where John Kerry was a founding member that has voiced support for liberal causes in the past.

Elon Musk is clashing with OpenAI CEO Sam Altman over the Stargate artificial intelligence infrastructure project touted by President Donald Trump, the latest in a feud between the two billionaires that started on OpenAI’s board and is now testing

The tech world is abuzz as two of its most prominent figures, Elon Musk and Sam Altman, have taken to social media to air their grievances over the controversial Stargate project. Also read: What a Liar: Elon Musk calls out Sam Altman over $10 billion equity in OpenAI report The very public spat between the Tesla and SpaceX CEO and OpenAI’s

Sam Altman has told OpenAI fans to lower their expectations after rumors the company had achieved AGI went viral on X.

Tensions between technology leaders Elon Musk and OpenAI CEO Sam Altman were on full display this week after the Tesla CEO slammed the new artificial intelligence (AI) infrastructure project,

More orders are expected Tuesday amid fallout from his first moves, including his issuing pardons for more than a thousand rioters convicted in connection with the violent Jan. 6 attack on the U.S. Capitol and his effort to end birthright citizenship.

The prime minister’s bumbling answer to a press club question on Australia’s engagement in the AI arms race shows how complacent political and business leaders are.

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through his support of Retro Biosciences, a San Francisco-based biotech startup. The company is currently in the process of raising $1 billion in a Series A funding round,